| pubmed-article:11996326 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11996326 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:11996326 | lifeskim:mentions | umls-concept:C0027481 | lld:lifeskim |
| pubmed-article:11996326 | lifeskim:mentions | umls-concept:C0042523 | lld:lifeskim |
| pubmed-article:11996326 | lifeskim:mentions | umls-concept:C0001758 | lld:lifeskim |
| pubmed-article:11996326 | lifeskim:mentions | umls-concept:C0085580 | lld:lifeskim |
| pubmed-article:11996326 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:11996326 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11996326 | pubmed:dateCreated | 2002-5-8 | lld:pubmed |
| pubmed-article:11996326 | pubmed:abstractText | The aim of this study was to evaluate the long term effects of the selective Ca2+-blocker verapamil on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. At the end of this clinical trial, plasma ANP levels increased by 16.14% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that verapamil exerts part of its antihypertensive action by increasing ANP plasma levels. | lld:pubmed |
| pubmed-article:11996326 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11996326 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11996326 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11996326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11996326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11996326 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11996326 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11996326 | pubmed:issn | 0378-7966 | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:PapadopoulosC... | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:KaramouzisMM | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:KokkasBB | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:SakadamisGG | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:KanonidisII | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:KotridisPP | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:PapadopoulosP... | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:Mirtsou-Fidan... | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:DadousGG | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:HaritosSS | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:KyriakouiPP | lld:pubmed |
| pubmed-article:11996326 | pubmed:author | pubmed-author:Theodossiadis | lld:pubmed |
| pubmed-article:11996326 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11996326 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:11996326 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11996326 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11996326 | pubmed:pagination | 45-8 | lld:pubmed |
| pubmed-article:11996326 | pubmed:dateRevised | 2011-2-2 | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:meshHeading | pubmed-meshheading:11996326... | lld:pubmed |
| pubmed-article:11996326 | pubmed:articleTitle | Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil. | lld:pubmed |
| pubmed-article:11996326 | pubmed:affiliation | Departments of Second Cardiology, Medical School, Aristotle University of Thesssaloniki, Greece. | lld:pubmed |
| pubmed-article:11996326 | pubmed:publicationType | Journal Article | lld:pubmed |
